Chaoju Eye Care Holdings Ltd.
2.33
HKD
-0.03
(-1.48%)
ISIN
KYG2047K1094
CUSIP
G2047K109
Return %
Stock
S&P 500
1Y
-9.69
14.20
3Y
-39.64
81.12
5Y
-74.08
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Bo Zhou Zhang
- Full Time Employees
- 2,590
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Shouke Building Beijing BE China 100071
- IPO Date
- Jul 7, 2021
- Website
- chaojueye.com
- Similar Companies
- Business
- Chaoju Eye Care Holdings Limited (2219.HK) operates a network of 31 ophthalmic hospitals and 29 optical centers across seven provinces, municipalities and autonomous regions in China, primarily in North China including Inner Mongolia, adjacent regions, Zhejiang, Jiangsu, Ningxia and Beijing; the company provides consumer ophthalmic services including refractive correction with presbyopia correction, myopia prevention and control, dry eye syndrome treatment, oculoplastic procedures and optical products and services not covered by public health insurance, as well as basic ophthalmic services covering cataract, glaucoma, squint, ocular fundus diseases, ocular surface diseases, orbital diseases and pediatric eye diseases mostly reimbursable under insurance programs, plus minor sales of equipment and medical consumables. Founded in 1988 in Baotou, Inner Mongolia, and headquartered at 24/F, East Zone, Block A, Shouke Building, No. 14 Yard, West 3rd Ring South Road, Fengtai District, Beijing, China, the group targets patients seeking specialized eye care through its clustered model in key regions like western and eastern Inner Mongolia, with inpatient and outpatient services supported by 1,500 full-time medical professionals including 320 physicians. In recent developments, the company announced acquisitions in 2025 including full buyout of Ningbo Boshi Eye Hospital for RMB14 million valuing it at RMB38 million and 70% stake in Wuzhong Yunshikang Eye Hospital for RMB5 million valuing it at RMB7.14 million to deepen presence in Zhejiang and Ningxia amid revenue contraction and profit decline in 2024; it maintains capital commitments of RMB69.3 million as of June 2025 for hospital renovations, equipment procurement and these deals, while subscribing RMB410 million in low-risk structured deposits for treasury management and planning network expansion in North China and Yangtze River Delta via further acquisitions and new builds, reporting 31 hospitals and 29 centers as of June 30, 2025 with revenue of RMB698.3 million for H1 2025 down 4.9% year-over-year.